open access

Vol 70, No 1 (2012)
Original articles
Published online: 2012-01-20
Submitted: 2012-12-28
Get Citation

Melatonin — a somniferous option which does not aggravate sleep−disordered breathing in cardiac risk patients: a Holter ECG based study

Tomasz Rechciński, Barbara Uznańska-Loch, Ewa Trzos, Karina Wierzbowska-Drabik, Maria Krzemińska-Pakuła, Jarosław D. Kasprzak, Małgorzata Kurpesa
Kardiol Pol 2012;70(1):24-29.

open access

Vol 70, No 1 (2012)
Original articles
Published online: 2012-01-20
Submitted: 2012-12-28

Abstract

Background and aim: We hypothesised that melatonin may represent a safe somniferous drug for cardiac patients, and assessed the effects of administering 5 mg of melatonin daily before bedtime for 30 days in patients with coronary artery disease (CAD) regarding changes in the nocturnal breathing pattern.
Methods: Sixty patients with CAD (aged 48–80 years) were randomised to melatonin/placebo treatment in a 2:1 ratio. A Holter ECG-based method (Lifescreen Apnea software) which has been validated as a screening tool for sleep-disordered breathing was used to estimate the apnoea/hypopnoea index (AHI). A 24-h Holter ECG was used to detect nocturnal breathing abnormalities at the beginning and at the end of the observation. The values of estimated AHI (eAHI) ≤ 15 were classified as optimal (Opt) and those > 15 — as pathological (Pat). A change of the breathing pattern was classified on the basis of the transition between the initial and final eAHI status (Opt→Opt; Opt→Pat; Pat→Pat, Pat→Opt). The mean initial and final value of eAHI and the percent of Opt and Pat values of eAHI in the initial and final assessment were compared between the melatonin and the placebo groups.
Results: The breathing pattern was not affected by melatonin — the mean initial value of the eAHI in the melatonin group was 18.2 ± 9.4, and in the placebo group 19.6 ± 12.3 (p = 0.64), whereas at the end of the observation in the melatonin group it increased by 1.2 ± 11.3, and in the placebo group — by 1.0 ± 9.0 (p = 0.44).
Conclusions: Hypnagogic treatment with melatonin did not worsen the eAHI in patients with CAD.
Kardiol Pol 2012; 70, 1: 24–29

Abstract

Background and aim: We hypothesised that melatonin may represent a safe somniferous drug for cardiac patients, and assessed the effects of administering 5 mg of melatonin daily before bedtime for 30 days in patients with coronary artery disease (CAD) regarding changes in the nocturnal breathing pattern.
Methods: Sixty patients with CAD (aged 48–80 years) were randomised to melatonin/placebo treatment in a 2:1 ratio. A Holter ECG-based method (Lifescreen Apnea software) which has been validated as a screening tool for sleep-disordered breathing was used to estimate the apnoea/hypopnoea index (AHI). A 24-h Holter ECG was used to detect nocturnal breathing abnormalities at the beginning and at the end of the observation. The values of estimated AHI (eAHI) ≤ 15 were classified as optimal (Opt) and those > 15 — as pathological (Pat). A change of the breathing pattern was classified on the basis of the transition between the initial and final eAHI status (Opt→Opt; Opt→Pat; Pat→Pat, Pat→Opt). The mean initial and final value of eAHI and the percent of Opt and Pat values of eAHI in the initial and final assessment were compared between the melatonin and the placebo groups.
Results: The breathing pattern was not affected by melatonin — the mean initial value of the eAHI in the melatonin group was 18.2 ± 9.4, and in the placebo group 19.6 ± 12.3 (p = 0.64), whereas at the end of the observation in the melatonin group it increased by 1.2 ± 11.3, and in the placebo group — by 1.0 ± 9.0 (p = 0.44).
Conclusions: Hypnagogic treatment with melatonin did not worsen the eAHI in patients with CAD.
Kardiol Pol 2012; 70, 1: 24–29
Get Citation

Keywords

melatonin; sleep apnoea syndrome; coronary artery disease

About this article
Title

Melatonin — a somniferous option which does not aggravate sleep−disordered breathing in cardiac risk patients: a Holter ECG based study

Journal

Kardiologia Polska (Polish Heart Journal)

Issue

Vol 70, No 1 (2012)

Pages

24-29

Published online

2012-01-20

Bibliographic record

Kardiol Pol 2012;70(1):24-29.

Keywords

melatonin
sleep apnoea syndrome
coronary artery disease

Authors

Tomasz Rechciński
Barbara Uznańska-Loch
Ewa Trzos
Karina Wierzbowska-Drabik
Maria Krzemińska-Pakuła
Jarosław D. Kasprzak
Małgorzata Kurpesa

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., Świętokrzyska 73 street, 80–180 Gdańsk, Poland

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl